Shattuck Labs, Inc. (STTK) stock

STTKNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30

$4.81−0.24 (-4.75%)

Close on Nov 12, 2026Market cap $482.75MP/E –Yield –

Shattuck Labs price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Shattuck Labs's price to sales ratio was 449.7× on May 29, 2026, against 10.5× a year earlier. Over the last 5 years it ranged from 3.2× to 490.0×, with a median of 75.2×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	May 29, 2026	449.7×	+219.2
2025	Dec 31, 2025	230.5×	+221.5
2024	Dec 31, 2024	9.0×	−218.3
2023	Dec 29, 2023	227.3×	+224.0
2022	Dec 30, 2022	3.2×	−277.4
2021	Dec 31, 2021	280.6×	+244.9
2020	Dec 31, 2020	35.7×	–

Where these numbers come from

Parsed from the XBRL in Shattuck Labs's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is STTK.

Compare: STTK vs IBIO · STTK vs YARW · STTK vs DNTH · STTK vs RNAC · STTK vs MCRB

Revenue growth-100.0% · median 115.0%

Company	Revenue	Growth
MCRB	$2.13M	+505.4%
IBIO	$1.08M	+115.0%
RNAC	$1.03M	–
YARW	$476.00K	-2.1%
STTK	$0	-100.0%
DNTH	–	–

Company

Next earnings (est.): Mar 4, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 40
Held by institutions: 83.5%
Auditor: KPMG LLP
SEC CIK: 1680367

Advertisement
300 × 250

See a number that looks wrong?

Shattuck Labs price to sales ratio

Price to Sales Ratio at the end of each year

More Shattuck Labs figures